Despite the development of new drugs and other therapeutic strategies, cardiovascular disease (CVD) remains still the major cause of morbidity and mortality in the world population. A lot of research, performed mostly in the last three decades, revealed an important correlation between "classical" demographic and biochemical risk factors for CVD, (i.e., hypercholesterolemia, hyperhomocysteinemia, smoking, renal failure, aging, diabetes, and hypertension) with endothelial dysfunction associated directly with the nitric oxide deficiency. The discovery of nitric oxide and its recognition as an endothelial-derived relaxing factor was a breakthrough in understanding the pathophysiology and development of cardiovascular system disorders. The nitric oxide synthesis pathway and its regulation and association with cardiovascular risk factors were a common subject for research during the last decades. As nitric oxide synthase, especially its endothelial isoform, which plays a crucial role in the regulation of NO bioavailability, inhibiting its function results in the increase in the cardiovascular risk pattern. Among agents altering the production of nitric oxide, asymmetric dimethylarginine-the competitive inhibitor of NOS-appears to be the most important. In this review paper, we summarize the role of L-arginine-nitric oxide pathway in cardiovascular disorders with the focus on intraplatelet metabolism.
Copyright © 2020 Jakub Gawrys et al.
Conflict of interest statement
The authors declare that they have no conflicts of interest.
Nitric oxide synthase inhibition and oxidative stress in cardiovascular diseases: possible therapeutic targets?Pharmacol Ther. 2013 Dec;140(3):239-57. doi: 10.1016/j.pharmthera.2013.07.004. Epub 2013 Jul 13. Pharmacol Ther. 2013. PMID: 23859953 Review.
Asymmetric dimethylarginine as a surrogate marker of endothelial dysfunction and cardiovascular risk in patients with systemic rheumatic diseases.Int J Mol Sci. 2012 Sep 26;13(10):12315-35. doi: 10.3390/ijms131012315. Int J Mol Sci. 2012. PMID: 23202900 Free PMC article. Review.
Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the "L-arginine paradox" and acts as a novel cardiovascular risk factor.J Nutr. 2004 Oct;134(10 Suppl):2842S-2847S; discussion 2853S. doi: 10.1093/jn/134.10.2842S. J Nutr. 2004. PMID: 15465797 Review.
[Asymmetric dimethylarginine: metabolism, arginine paradox, pathophysiology].Usp Fiziol Nauk. 2007 Jul-Sep;38(3):21-39. Usp Fiziol Nauk. 2007. PMID: 17977229 Review. Russian.
Effect of asymmetric dimethylarginine (ADMA) on heart failure development.Nitric Oxide. 2016 Apr 1;54:73-81. doi: 10.1016/j.niox.2016.02.006. Epub 2016 Feb 24. Nitric Oxide. 2016. PMID: 26923818 Free PMC article. Review.